Insights on Improving Global Drug Development from Bench to Commercialization

Although R&D spending on new drugs is high and the number of new INDs for small molecules and biologics continues to increase each year, the number of NDAs/BLAs submitted and approved by FDA has remained on average steady over the last 10 years.

Spotlight

POINT Biopharma

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

OTHER VIDEOS

The Cardinal Health™ InteLogix™ Platform

video | September 6, 2023

Learn about the industry’s first pharmaceutical supply chain solution that is reducing the cost of care and ensuring access to critical medications for hospitals and health systems....

Watch Now

Aeris: Benchtop XRD for pharmaceutical solid form analysis

video | August 28, 2023

Is solid form characterization critical in your line of work, but you lack expertise in X-ray diffraction (XRD)? Do you need an efficient tool to support you with lead optimization? Do you need an easy way to validate the stability of your solid form following processing?...

Watch Now

Semi-automated testing of on-body delivery systems (OBDS)

video | August 17, 2023

Injection systems that are attached to the patient's body (on-body delivery system OBDS) minimize possible risks, that can occur when drugs are administered by conventional needle-based injection systems (NIS)....

Watch Now

Line Optimizer - digital guided workflows for optimized pharma production operations

video | May 26, 2023

Connectivity in general is becoming an ever more important consideration for production facilities as we endeavour to produce more with less and all the while trying to satisfy an increasing need for more information and communication to and from the production equipment itself....

Watch Now

Spotlight

POINT Biopharma

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

Events